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Background: Given the importance of complementary and alternative medicine (CAM) to cancer patients, there is
an increasing need to learn more about possible interactions between CAM and anticancer drugs. Mistletoe
(Viscum album L.) belongs to the medicinal herbs that are used as supportive care during chemotherapy. In the
in vitro study presented here the effect of standardized mistletoe preparations on the cytostatic and cytotoxic
activity of several common conventional chemotherapeutic drugs was investigated using different cancer cell lines.
Methods: Human breast carcinoma cell lines HCC1937 and HCC1143 were treated with doxorubicin hydrochloride,
pancreas adenocarcinoma cell line PA-TU-8902 with gemcitabine hydrochloride, prostate carcinoma cell line DU145
with docetaxel and mitoxantrone hydrochloride and lung carcinoma cell line NCI-H460 was treated with docetaxel
and cisplatin. Each dose of the respective chemotherapeutic drug was combined with Viscum album extract (VAE)
in clinically relevant concentrations and proliferation and apoptosis were measured.
Results: VAE did not inhibit chemotherapy induced cytostasis and cytotoxicity in any of our experimental settings.
At higher concentrations VAE showed an additive inhibitory effect.
Conclusions: Our in vitro results suggest that no risk of safety by herb drug interactions has to be expected from
the exposition of cancer cells to chemotherapeutic drugs and VAE simultaneously.
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A primary cytotoxic mechanism of many conventional
anticancer agents is based on the damage of DNA and
the subsequent induction of apoptosis. Beside cytotoxic
reactions cancer cells can also respond by cell cycle
block or delay (cytostasis) [1]. Because chemotherapeutic
agents preferably act on rapidly dividing normal cells,
therapeutic treatments result in common side-effects
like myelosuppression, hair loss, fatigue, infection etc. In
an attempt to reduce the clinical toxicity of chemothera-
peutic drugs, to consolidate the immune system and to
improve the symptoms of their disease many cancer pa-
tients use mistletoe extracts as a complementary therapy
in combination with standard regimens [2,3].* Correspondence: u.weissenstein@vfk.ch
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article, unless otherwise stated.Mistletoe (Viscum album) preparations contain active
components like mistletoe lectins and viscotoxins and
are reported to show anti-tumoral properties by causing
cell cycle delay or arrest and induction of apoptosis
[4-7], affecting tumor angiogenesis [8,9] and exerting
immune-potentiating activities that may enhance the
host defense system against tumors [10-13]. Molecular
compounds of mistletoe are reported to show in vitro
inhibitory potential on P-glycoprotein (P-gp) also known
as multidrug resistance protein 1 (MDR1) [14]. The ana-
lysis of clinical studies suggests that adjuvant treatment
of cancer patients with mistletoe extracts is associated
with a better survival, a reduction of side effects of con-
ventional therapy and with an increase of quality of life
[15-18]. In early stage breast cancer patients the fre-
quency of relapse or metastasis within 5 years was not
influenced by additional mistletoe therapy [19].entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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tients to use complementary therapies, sometimes are
concerned about possible interactions of herbal medi-
cines with oncological drugs, which could influence the
efficacy of the standard treatment.
The aim of our study therefore was to investigate pos-
sible effects of clinically relevant doses of standardized
VAEs on the cytostatic and cytotoxic efficacy of several
standard chemotherapeutic agents on different cancer
cell lines in vitro.
Methods
Mistletoe extracts and chemotherapeutic drugs
The aqueous, fermented mistletoe preparations Iscador
M spec. 5 mg (VAE-M, host tree Malus domestica,
Lot 1109/2103/2, total mistletoe lectin concentration
287 ng/ml) and Iscador Qu spec. 5 mg (VAE-Qu, host
tree Quercus robur and Q. petraea, Lot 1204/2221/4,
total mistletoe lectin concentration 399 ng/ml) were ob-
tained from the Society for Cancer Research (Arlesheim,
Switzerland).
Doxorubicin hydrochloride, gemcitabine hydrochlor-
ide, docetaxel, and mitoxantrone hydrochloride were ob-
tained from Sigma-Aldrich Logistik GmbH (Buchs, CH)
and cisplatin from LuBio Science GmbH (Lucerne, CH).
Cell culture
Human breast carcinoma cell lines HCC1937 and
HCC1143, pancreas adenocarcinoma cell line PA-TU-
8902, prostate carcinoma cell line DU145 and lung car-
cinoma cell line NCI-H460 were obtained from DSMZ
(German Collection of Microorganisms and Cell Cul-
tures, Braunschweig, Germany).
HCC1937, HCC1143, DU145 and NCI-H460 cells
were cultured in RPMI-1640 supplemented with 10%
fetal calf serum, 2 mM L-glutamine, and 1% Penicillin –
Streptomycin (Sigma-Aldrich). PA-TU-8902 cells were
cultured in Dulbecco’s MEM High Glucose (Sigma-Al-
drich) supplemented with 2 mM L-Glutamine, 1 mM
Sodium Pyruvate, 10% fetal calf serum and 1% Penicillin –
Streptomycin in a humidified atmosphere with 5% CO2 at
37°C. Cell lines were maintained in exponential growth
and cells from subconfluent monolayers were harvested
by trypsin-EDTA (Sigma-Aldrich) to carry out the experi-
ments. For measurement of the parameters, the cell cul-
tures were used within 4–6 weeks after thawing.
Proliferation assay
Proliferation was indirectly assessed using the cell prolif-
eration reagent WST-1 (Roche, Mannheim, Germany).
Cells (1.5 × 104 in 100 μl) were plated in triplicates in
96-well plates. After 4–6 hours to allow attachment, the
drugs were added in various concentrations (see below).
Proliferation rate was measured 4 h after incubationwith the reagent in triplicate. The upper limit of absorb-
ance was 2.0 - 2.1. Values are given in percent inhibition
of proliferation relative to untreated control.
Cell death analysis
Apoptosis/necrosis was measured using the Annexin V-
FITC Apoptosis Detection Kit I (BD Biosciences Phar-
mingen™, San Diego, CA, USA). Briefly: 2x105 cells were
incubated with Annexin V-FITC and 7-AAD at room
temperature in the dark. Thereafter, the samples were
analysed in a flow cytometer (FACS Calibur, BD Bio-
sciences, San Jose, CA). Early apoptotic cells: Annexin
V-FITC positive and 7-AAD negative. Late apoptotic/
necrotic cells: Annexin V-FITC positive and 7-AAD po-
sitive. Values are given in percent of total cell number.
Cytotoxicity (%) was calculated as follows: early apop-
totic cells (%) + late apoptotic/necrotic cells (%).
Drug concentrations in the assays
Preceding the actual experiments the dose–response
concentration range and the optimal incubation time
was determined for each chemotherapeutic agent and
each cell line individually using the WST-1 proliferation
assay (data not shown). Cells were incubated for 48 h or
72 h respectively, depending on the maximal measurable
anti-proliferative effect of cytostatic agents. Because of
its own fluorescence, doxorubicin at higher doses inter-
fered with the nucleic acid dye 7-AAD. Therefore the
maximal doxorubicin concentration usable for the detec-
tion of apoptosis in the breast carcinoma cell lines
HCC1143 and HCC1937 was 5 μg/ml.
In the main experiments, the drugs were added in cul-
ture medium at the concentrations indicated in Table 1.
Each dose of the respective chemotherapeutic drug was
combined with VAE-M (HCC1937 and HCC1143) or
VAE-Qu (PA-TU-8902, DU-145 and NCI-H460) at the
concentrations of 0; 0.1; 1.0; 10; 100 μg/ml for the meas-
urement of proliferation and of 0; 0.1; 1.0; 10 μg/ml for
the measurement of apoptosis/necrosis. Typical clinical
Iscador concentrations for subcutaneous application are
0.1 and 1 μg/ml, roughly corresponding to an injection
of 5 mg Iscador when referring to the amount of circu-
lating blood or body weight, respectively. Parameters
were measured after the appropriate incubation time.
As we intended to detect a minimal dose able to in-
duce apoptosis in PA-TU-8902 cells we used consider-
ably higher gemcitabine concentrations in apoptosis
than in proliferation assay.
Data analysis
Three independent experiments were carried out for each
combination of chemotherapeutic drug and mistletoe ex-
tract. Data were analyzed with 2-way analysis of variance




Concentrations of chemotherapeutic drug (μg/ml) for Incubation
time (h)Proliferation assay Apoptosis assay
HCC1937 Doxorubicin hydroxide 0.0; 0.1; 0.5; 1.0; 5.0 0.0; 0.25; 1.0; 5.0 48
HCC1143 Doxorubicin hydroxide 0.0; 0.1; 0.5; 1.0; 5.0 0.0; 0.5; 5.0 48
PA-TU-8902 Gemcitabine hydroxide 0.0; 0.01; 0.1; 1.0; 10.0 0.0; 25.0; 50.0; 100.0; 200.0 72
DU-145 Docetaxel 0.0; 0.0008; 0.008; 0.08; 0.8 0.0; 0.0008; 0.008; 0.08; 0.8 72
DU-145 Mitoxantrone hydroxide 0.0; 0.002; 0,02; 0,2; 2.0 0.0; 0.002; 0,02; 0,2; 2.0 72
NCI-H460 Cisplatin 0.0; 0.3; 1.0; 3.0; 9.0 0.0; 0.3; 1.0; 3.0; 9.0 48
NCI-H460 Docetaxel 0.0; 0.001; 0.01; 0.1; 1.0 0.0; 0.001; 0.01; 0.1; 1.0 48
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(Statsoft Inc., Tulsa, USA). For pairwise comparisons, the
protected Fisher LSD-test was used. This procedure gives
a good safeguard against false-positive as well as false-
negative errors [20]. Limit of significance was defined as
p < 0.05.
Results
Effects of VAE on proliferation and apoptosis of cancer
cell lines
The growth kinetic analysis of five cancer cell lines re-
vealed a dose dependent anti-proliferative effect of VAE
at concentrations ≥10 μg/ml except for the pancreas car-
cinoma cell line PA-TU-8902 and the lung carcinoma
cell line NCI-H460, where a proliferation inhibition
could only be detected with 100 μg/ml (p < 0.05). The
doses of 0.1 and 1 μg/ml VAE did not significantly influ-
ence the proliferation of tumor cells (Figure 1A,B). In all
five cell lines (after 48 or 72 hours incubation, see
Table 1) VAE concentrations between 0.1 and 10 μg/ml
did not result in an elevated proportion of apoptotic and
necrotic cells (p > 0.5, Figure 1C-F).
Effects of a combined application of VAE and
chemotherapeutic drugs on proliferation and apoptosis/
necrosis in cancer cells
Figure 2 presents the mean values of proliferation, early
apoptosis and late apoptosis/necrosis of the breast car-
cinoma cell lines HCC1143 and HCC1937 treated with
different concentrations of doxorubicin in combination
with different concentrations of VAE-M.
For HCC1143, the maximal cytostatic effect attained
by the treatment with doxorubicin or VAE-M alone was
about 75% or 65%, respectively. VAE-M generally enforced
the antiproliferative effect of doxorubicin (Figure 2A). This
enforcement was significant for 100 μg/ml VAE-M, com-
pared to 0 μg/ml VAE-M, for the doxorubicin concentra-
tions of 0.1–1 μg/ml (p < 0.01).
For HCC1937, the maximal cytostatic effect attained by
the treatment with doxorubicin or VAE-M alone was about80% or 45%, respectively. VAE-M ≥10 μg/ml enforced the
antiproliferative effect of doxorubicin (Figure 2B). This en-
forcement was significant for 100 μg/ml VAE-M, compared
to 0 μg/ml VAE-M, for all doxorubicin concentrations ap-
plied (p < 0.05).
A trend for an enhancement of the anti-proliferative
effect of doxorubicin by VAE-M at the clinical relevant
concentrations 0.1 and 1 μg/ml could be observed in the
HCC1143 cell line, but not in HCC1937. This enforce-
ment was not statistically significant.
According to the apoptosis measurements, doxorubicin
exerted a dose dependent cytotoxic effect on HCC1143
and HCC1937 cells (p < 0.001). Maximal cytotoxicity mea-
sured was 60% and 75%, respectively. VAE-M at con-
centrations between 0.1 and 10 μg/ml neither induced
cytotoxic effects nor influenced the cytotoxic effect of
doxorubicin in both cell lines (p > 0.05) (Figure 2C,E,D,F).
In the pancreatic carcinoma cell line PA-TU-8902 the
maximal inhibition of proliferation attained by the treat-
ment with 10 μg/ml gemcitabine or 100 μg/ml VAE-Qu
alone was about 60% or 35%, respectively. Proliferation
inhibition through gemcitabine could not be augmented
further by dose enhancement of gemcitabine (data not
shown). Only VAE-Qu at a concentration of 100 μg/ml
resulted in an additional increase of the antiproliferative
effect (p < 0.001) compared to VAE-Qu = 0 μg/ml for all
gemcitabine concentrations. The pancreatic carcinoma
cell line PA-TU-8902 was strongly apoptosis resistant. In
this cell line the maximal cytotoxicity after 72 hours in-
cubation was about 15% compared to 9% in the un-
treated control for all gemcitabine doses between 25 and
200 μg/ml and no concentration dependency was ob-
served. VAE-Qu at concentrations between 0.1 and
10 μg/ml neither induced apoptosis nor influenced the
cytotoxic effect of gemcitabine (p > 0.05, Figure 3).
The prostate carcinoma cell line DU145 was treated
with the chemotherapeutic agents docetaxel or mito-
xantrone, respectively, as well as VAE-Qu in various
concentrations. The maximal cytostatic effect of all
drugs applied alone was about 90%. An enforcement of
Figure 1 Dose dependent anti-proliferative effect of A) VAE-M and B) VAE-Q and effect of VAE-M on C) early and E) late apoptosis/
necrosis and of VAE-Qu on D) early and F) late apoptosis/necrosis of five cancer cell lines. Results are presented as mean ± SD from three
independent experiments. Cell growth kinetic was assessed with the WST-1 assay. Apoptosis was measured by flow cytometric analysis of
Annexin V-FITC and 7-AAD double-labeled cells.
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Qu concentrations of ≥10 μg/ml (p < 0.01) for medium
concentrations of docetaxel (0.0008, 0.008 μg/ml) or
mitoxantrone (0.002, 0.02 μg/ml) (Figure 4A,B).
Docetaxel and mitoxantrone exerted a dose dependent
cytotoxic effect on DU145 cells with a maximum of
about 50% cytotoxicity each (p < 0.001; Figure 4C–F).
Doses between 0.1 and 10 μg/ml of VAE-Qu did not in-
fluence the cytotoxic effect of both chemotherapeutic
agents (p > 0.05), with the exception of 10 μg/ml VAE-
Qu at 0.2 μg/ml mitoxantrone (p < 0.05).
The treatment of the lung carcinoma cell line NCI-
H460 with cisplatin at a concentration of 9 μg/ml re-
sulted in a proliferation inhibition of 95% (Figure 5A),
whilst VAE-Qu (100 μg/ml) inhibited proliferation by
50% (Figure 5A,B). The maximal cytostatic effect at-
tained by the treatment with docetaxel (1 μg/ml) was
about 40% and – as in PA-TU-8902 cells – could not
further be augmented by dose enhancement (Figure 5B).Only VAE-Qu at a concentration of 100 μg/ml could
additionally enhance the antiproliferative effect of do-
cetaxel (Figure 5B), as it did for 0.3–3 μg/ml cisplatin
(Figure 5A).
The dose dependent cytotoxic effect of cisplatin and
docetaxel on NCI-H460 revealed a maximal cytotoxicity
for cisplatin of 85% and for docetaxel of 55%. In general,
no significant influence of VAE-Qu at concentrations be-
tween 0.1 and 10 μg/ml was observed; only at 3 μg/ml
cisplatin, VAE-Qu 1 and 10 μg/ml additionally enhanced
early apoptosis (p < 0.05, Figure 5C), as did 10 μg/ml
VAE-Qu at 0.01 and 0.1 μg/ml docetaxel (p < 0.05,
Figure 5D).
Discussion
No inhibition of chemotherapy-induced cytostasis by
VAE was observed in any of our experimental settings.
In general, VAE at concentrations between 0.1 and
10 μg/ml neither enhanced nor decreased the amount of
Figure 3 Mean values (±SD) of (A) proliferation, (B) early apoptosis and (C) late apoptosis/necrosis of pancreatic carcinoma cell line
PA-TU-8902 treated with different concentrations of gemcitabine combined with different concentrations of VAE-Qu.
Figure 2 Mean values (±SD) of (A,B) proliferation, (C,D) early apoptosis and (E,F) late apoptosis/necrosis of breast carcinoma cell lines
HCC1143 (A,C,E) and HCC1937 (B,D,F) treated with different concentrations of doxorubicin combined with different concentrations
of VAE-M.
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Figure 4 Mean values (±SD) of (A,B) proliferation, (C,D) early apoptosis and (E,F) late apoptosis/necrosis of prostate carcinoma cell line
DU145 treated with different concentrations of docetaxel (A,C,E) or mitoxantrone (B,D,F), respectively combined with different
concentrations of VAE-Qu.
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crosis. At concentrations ≥10 μg/ml, VAE led to an addi-
tive augmentation of chemotherapy induced cytostasis.
Since cancer patients receive besides anticancer agents
numerous medications for supportive care and treatment
of comorbid illnesses, consideration of metabolic inter-
actions is important. Drug interactions could influence
efficacy and toxicity of cytostatic drugs. For example cyto-
toxicity of taxanes which stabilize microtubule structures
and thereby block the mitotic spindle apparatus is very
susceptible to drugs that induce cell cycle arrest. Their ef-
fect can be potentiated or antagonized depending on the
sequence of applied drugs [21].
Although mistletoe is frequently used in addition to
conventional cancer therapeutics, there is only little in-
formation about possible interactions with chemothera-
peutic drugs. Many anticancer drugs are metabolized by
cytochrome P isoenzymes (CYPs) and the metabolism
and pharmacokinetics of anticancer agents may be al-
tered by herbal medicines. Thus, inhibition of CYPs
could affect the intracellular concentration of drugs.Mistletoe was reported to be an inhibitor of CYP3A4
in vitro [22], however, the corresponding IC50 values are
physiologically irrelevant. The investigation of interfer-
ences of mistletoe with cytochrome P450 isoforms in
human hepatocytes indicated no or only minor potential
for herb-drug interactions [23], suggesting that clinically
significant systemic interaction is unlikely.
The aim of our study was to investigate if clinically rele-
vant doses of VAE interfere with standard chemotherapeutic
agents in vitro by influencing their cytostatic and cytotoxic
efficacy. We used the standard chemotherapeutic drugs
doxorubicin for the treatment of breast cancer cell lines
HCC1141 and HCC1937 [24], gemcitabine for the treat-
ment of pancreatic carcinoma cell line PA-TU-8902 [25],
mitoxantrone and docetaxel for the treatment of prostate
cancer cell line DU145 [26] and cisplatin and docetaxel for
the treatment of lung carcinoma cell line NCI-H460 [27].
According to typical usage in integrative oncological set-
tings, Iscador M spec. (VAE-M) was used for the treatment
of breast and Iscador Qu spec. (VAE-Qu) for the treatment
of pancreatic, prostate and lung cancer cell lines [19,28,29].
Figure 5 Mean values (±SD) of (A,B) proliferation, (C,D) early apoptosis and (E,F) late apoptosis/necrosis of lung carcinoma cell line
NCI-H460 treated with different concentrations of cisplatin (A,C,E) or docetaxel (B,D,F), respectively, combined with different
concentrations of VAE-Qu.
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demonstrate the well known anti-proliferative effects of
higher doses of mistletoe extracts on cancer cell lines.
The direct anti-proliferative and cytotoxic activity of
mistletoe is based mainly on a dose dependent apoptotic
effect of mistletoe lectins (ML) [30] which in case of ML
I requires the internalization of its A chain that inacti-
vates the 28 S ribosomal subunit leading to inhibition of
protein synthesis and to induction of apoptosis via the
intrinsic pathway [31-33]. Growth inhibition by mistle-
toe may also be the result of a cell cycle blockade in G0/
G1 phase [34]. High concentrations of ML and viscotox-
ins cause cell lysis mainly through necrosis [35,36].
In the context of supportive therapy with chemother-
apy protocols, where no direct induction of tumor-cell
specific apoptosis by mistletoe is intended, patients usu-
ally are treated with VAE doses between 0.01 and 20 mg
by 2 to 3 weekly subcutaneous injections. The concen-
trations of 0.1 and 1 μg/ml VAE are roughly correspond-
ing to an injection of 5 mg Iscador when referring to the
amount of circulating blood or body weight, respectively.Our results show that these lower, clinically typical VAE
doses influenced neither proliferation nor apoptosis of
the investigated cell lines.
VAE concentrations ≥10 μg/ml partially had an addi-
tive effect on chemotherapy induced cytostasis. Additive
effects were previously shown in highly ML-sensitive
Jurkat cells, where very low nontoxic concentrations of
purified ML-I markedly enhanced etopside-induced apop-
tosis [33]. Siegle et al. demonstrated additive cytotoxic
activity of Viscum album agglutinin-I (VAA-I) in combi-
nation with doxorubicin, cisplatin and taxol in the human
lung carcinoma cell line A549 [37].
In vitro determination of cytostasis or cytotoxicity de-
pends on assay conditions like doses used, incubation
time and the cellular context. In our experiments, the
cytostatic effects distinctly exceeded the cytotoxic ef-
fects for the chemotherapeutic agents and VAE alone
or in combination. Most of the conventional antican-
cer agents are both cytostatic and cytotoxic [1]. Cytostasis
can be the initial step for different mechanisms of cell
death whereby the duration of mitotic arrest does not
Weissenstein et al. BMC Complementary and Alternative Medicine 2014, 14:6 Page 8 of 9
http://www.biomedcentral.com/1472-6882/14/6necessarily correlate with the probability of death [38]. In
apoptosis-sensitive cell lines, prolonged mitotic arrest in-
duced by antimitotic drugs causes apoptosis. In less sensi-
tive cell lines, cells undergo slippage without division into
tetraploid G1, which may be followed by p53-dependent
arrest, apoptosis, or another round of mitosis [38-41]. On
the other hand it is well known that mutations in the
apoptotic program (i.e. p53 mutations) and up-regulated
pro-survival signals (anti-apoptotic Bcl2 family members)
in established cancers contribute to resistance to apoptotic
cell death and are important aspects of resistance to anti-
cancer therapies [42,43].
Iscador adjuvant to chemotherapy was reported to de-
crease therapy-related adverse drug reactions, to in-
crease response rates and to improve disease symptom
control, quality of life and overall survival [15,18,44,45].
In vitro and in vivo studies revealed several effects that
may contribute to explain the mistletoe related clinical
benefits. In cyclophosphamide exposed cells in vitro,
mistletoe extracts exerted a protective effect on periph-
eral mononuclear cells (PBMC) from healthy donors but
not on malignant Jurkat leukemia cells by the enhance-
ment of mitochondrial activity and replication [46]. In
PBMC, mistletoe extracts improved DNA repair of dam-
aged cells [47] and reduced sister chromatide exchange
[48]. Numerous effects of mistletoe extracts on the im-
mune system are known [11]. It is hypothesized that
these immunomodulating properties augment systemic
antitumor effects and contribute to a reduction of
chemotherapy-associated immune suppression.
Cancer cell lines have been widely used to study the
biological mechanisms involved in cancer and to exam-
ine the factors influencing the response of tumors to
therapeutic agents and regimens. In general, cancer cell
lines show similar morphologic and molecular character-
istics of the primary tumor and maintain the expression
of most cancer characteristics. However, they also have a
major disadvantage. Cells are removed from their natural
environment and interaction and protection mechanisms
otherwise available from the donor organism are elimi-
nated. Cancer cell lines often originate from aggressive
and metastatic tumors and may not properly reflect the
situation in earlier stage and lower grade disease. These
factors must be considered when interpreting the results
of our study.
Testing the effect of mistletoe extracts on chemothera-
peutics in vitro with a limited number of cell lines and
test substances is a basic step in completing the know-
ledge about possible herb-drug interactions and cannot
replace clinical investigations.
Conclusions
Aqueous, fermented mistletoe extracts did not influence
the cytostatic and cytotoxic activity of several commonconventional chemotherapeutic drugs when applied in
concentrations typical for clinical use. We could show
this in breast, prostate, pancreatic and lung carcinoma
cell lines. Although these in vitro data cannot directly be
extrapolated to the complex in vivo conditions, they
contribute to the knowledge regarding safety of cancer
patients receiving mistletoe supported chemotherapy.
Our in vitro results are in line with clinical experiences
and trials that Iscador can be used concomitant with
conventional oncological drugs without safety hazard by
herb drug interactions.
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